PL1754713T3 - Peptydy wiążące się z receptorem APO2L (TRAIL) oraz ich zastosowanie - Google Patents

Peptydy wiążące się z receptorem APO2L (TRAIL) oraz ich zastosowanie

Info

Publication number
PL1754713T3
PL1754713T3 PL06013626T PL06013626T PL1754713T3 PL 1754713 T3 PL1754713 T3 PL 1754713T3 PL 06013626 T PL06013626 T PL 06013626T PL 06013626 T PL06013626 T PL 06013626T PL 1754713 T3 PL1754713 T3 PL 1754713T3
Authority
PL
Poland
Prior art keywords
apo2l
trail
receptor binding
binding peptides
apo
Prior art date
Application number
PL06013626T
Other languages
English (en)
Inventor
Bing Li
Sachdev S Sidhu
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PL1754713T3 publication Critical patent/PL1754713T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL06013626T 2003-05-09 2004-04-29 Peptydy wiążące się z receptorem APO2L (TRAIL) oraz ich zastosowanie PL1754713T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46943603P 2003-05-09 2003-05-09
EP06013626A EP1754713B1 (en) 2003-05-09 2004-04-29 Apo2L (Trail) receptor binding peptides and uses thereof
EP04760861A EP1622929B1 (en) 2003-05-09 2004-04-29 Apo2l (trail) receptor binding peptides and uses thereof

Publications (1)

Publication Number Publication Date
PL1754713T3 true PL1754713T3 (pl) 2009-07-31

Family

ID=33452286

Family Applications (2)

Application Number Title Priority Date Filing Date
PL06013626T PL1754713T3 (pl) 2003-05-09 2004-04-29 Peptydy wiążące się z receptorem APO2L (TRAIL) oraz ich zastosowanie
PL04760861T PL1622929T3 (pl) 2003-05-09 2004-04-29 Peptydy wiążące się z receptorem APO2L(TRAIL) oraz ich zastosowanie

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL04760861T PL1622929T3 (pl) 2003-05-09 2004-04-29 Peptydy wiążące się z receptorem APO2L(TRAIL) oraz ich zastosowanie

Country Status (12)

Country Link
US (1) US20070066800A1 (pl)
EP (2) EP1622929B1 (pl)
JP (1) JP2007530008A (pl)
AT (2) ATE342274T1 (pl)
AU (1) AU2004238794A1 (pl)
CA (1) CA2524456A1 (pl)
DE (2) DE602004019701D1 (pl)
DK (2) DK1754713T3 (pl)
ES (2) ES2274480T3 (pl)
IL (1) IL171733A (pl)
PL (2) PL1754713T3 (pl)
WO (1) WO2004101608A2 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0509201A (pt) 2004-03-23 2007-08-28 Biogen Idec Inc agentes de acoplamento de receptor e usos terapêuticos destes
US20060188498A1 (en) * 2005-02-18 2006-08-24 Genentech, Inc. Methods of using death receptor agonists and EGFR inhibitors
US20090131317A1 (en) * 2007-06-22 2009-05-21 Affymax, Inc. Compounds and peptides that bind the trail receptor
CA2749512A1 (en) * 2009-04-03 2010-10-07 Institute Of Basic Medical Sciences, Chinese Academy Of Medical Sciences Antigenic determinants recognized by anti-human death receptor dr5 monoclonal antibody ad5-10, derivatives and use thereof
JP2013507124A (ja) * 2009-10-09 2013-03-04 アナフォア インコーポレイテッド Ｉｌ−２３ｒを結合するポリペプチド
US11299528B2 (en) 2014-03-11 2022-04-12 D&D Pharmatech Inc. Long acting TRAIL receptor agonists for treatment of autoimmune diseases
FR3031112B1 (fr) * 2014-12-24 2018-05-25 Eyevensys Construction d'adn pour le traitement de pathologies oculaires
CN105061604B (zh) * 2015-08-19 2018-03-16 河南大学 sDR5‑Fc融合蛋白突变体及其应用
US11007251B2 (en) 2015-12-17 2021-05-18 The Johns Hopkins University Ameliorating systemic sclerosis with death receptor agonists
AU2017248264B2 (en) 2016-04-07 2020-01-30 The Johns Hopkins University Compositions and methods for treating pancreatitis and pain with death receptor agonists
CN116585484B (zh) * 2022-12-13 2023-12-12 广州医科大学 多肽偶联小分子化合物及其抗病毒应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6252050B1 (en) * 1998-06-12 2001-06-26 Genentech, Inc. Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method

Also Published As

Publication number Publication date
EP1754713A1 (en) 2007-02-21
AU2004238794A1 (en) 2004-11-25
CA2524456A1 (en) 2004-11-25
WO2004101608A3 (en) 2004-12-29
ES2322182T3 (es) 2009-06-17
ATE342274T1 (de) 2006-11-15
DE602004002773D1 (de) 2006-11-23
DK1754713T3 (da) 2009-06-08
DE602004002773T2 (de) 2007-08-16
PL1622929T3 (pl) 2007-03-30
DE602004019701D1 (de) 2009-04-09
WO2004101608A2 (en) 2004-11-25
DK1622929T3 (da) 2007-02-19
ATE423786T1 (de) 2009-03-15
IL171733A (en) 2010-11-30
EP1622929A2 (en) 2006-02-08
EP1754713B1 (en) 2009-02-25
JP2007530008A (ja) 2007-11-01
EP1622929B1 (en) 2006-10-11
ES2274480T3 (es) 2007-05-16
US20070066800A1 (en) 2007-03-22

Similar Documents

Publication Publication Date Title
IL158920A0 (en) Taci-immunoglobulin fusion proteins
IL161016A (en) Polypeptides capable of ang-2 binding
WO2005047327A8 (en) NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
EP2267019A3 (en) Binding polypeptides for B lymphocyte stimulator protein (BLyS)
WO2006076594A3 (en) Antibodies and fc fusion proteins with altered immunogenicity
IL171733A (en) Apo2l (trail) receptor binding peptides and uses thereof
WO2007079218A3 (en) Metalloproteinase binding proteins
WO2004013290A3 (en) Compositions and methods for molecular biology
DK1536778T3 (da) Proteiner, der binder til cross-beta-strukturholdigt amyloid og fremgangsmåder til modulation af cross-beta-strukturen, dens dannelse og dens associerede toksicitet
WO2002062957A3 (en) Ter sites and ter binding proteins
EP1978994A4 (en) BMP-7 VARIANTS COMPOSITIONS, METHODS AND USES
AU2003261102A1 (en) Novel polynucleotide and polypeptide sequences and uses thereof
MX2010003892A (es) Polipeptidos modificados de la hormona del crecimiento.
WO2003100379A3 (en) Methods and reagents for removing contaminants from biomolecules
HK1095338A (en) Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
HK1088255A (en) Antibodies and fusion proteins that include engineered constant regions